While a 22 June US Supreme Court ruling that was peppered with Spider-Man puns may have provided some comic relief to legal watchers – although the loser in Kimble v Marvel likely didn't find much to laugh about – the case may help patent holders and those that enter into licensing rights deals, including biopharmaceutical makers, better understand and be more aware of a nearly half-century old case law rule.
In a 6-3 decision, the justices said they were unwilling to change a standard set by the Supreme Court itself...
